Key facts
- It has raised $3.2M; the latest was Accelerator/Incubator ($120K) in Dec 2025.
- Notable investors include Defence Innovation Accelerator for the North Atlantic, Genome British Columbia, HATCH Venture Builder, Little Green Bamboo Capital, The University of British Columbia — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Avivo
- ·The full record, as it builds
Funding rounds
No funding rounds for Avivo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avivo
Developer of a health-tech platform intended to make blood groups irrelevant for transfusion or organ transplant. The company's platform uses a proprietary technology that is a combination of two enzymes that first prime and then eliminate a marker on the red blood cell that determines blood group A, enabling hospitals to use any blood type for any patient safely.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2020
- Employees
- 14
- Website
- avivobio.com/
- Ownership
- Privately Held (backing)
Avivo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avivo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avivo in its N-PORT filings yet. We sweep new filings monthly.